May 19, 2023

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, D.C. 20549

 

	Re:	Agile Therapeutics, Inc.
		Registration Statement on Form S-1 (File No. 333-271249)
		Concurrence in Acceleration Request

 

Ladies and Gentlemen:

 

H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Agile Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to Monday, May 22, 2023, at 3:00 p.m. (Washington, D.C. time), or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement. 

 

	Very truly yours,
	H.C. WAINWRIGHT & CO., LLC
	By:	/s/ Edward D. Silvera
		Name: Edward D. Silvera
		Title: Chief Operating Officer